ATI RN
ATI Capstone Pharmacology Assessment 2 Quizlet Questions
Question 1 of 5
Which of the following is the systemic treatment of choice for female hirsutism?
Correct Answer: D
Rationale: Hirsutism involves excess androgen-driven hair growth. Tamoxifen, an estrogen modulator, treats breast cancer, not hirsutism. Ethinylestradiol reduces androgens via SHBG increase, but alone isn't optimal. Norethisterone, a progestin, may worsen hirsutism. Finasteride blocks 5-alpha-reductase, reducing DHT, but cyproterone, an anti-androgen, directly inhibits androgen receptors and gonadotropin release, the systemic choice for hirsutism (e.g., in PCOS). Its potency targets the root cause, offering effective hair reduction.
Question 2 of 5
Drugs may be excreted by any route in the body, except:
Correct Answer: D
Rationale: Saliva is not a common route for drug excretion. Drugs are primarily excreted from the body through various routes such as the kidneys (urine), lungs (exhaled air), gastrointestinal tract (feces), and tears (through the eyes). Saliva does not play a major role in drug excretion, as most drugs are not significantly eliminated through saliva.
Question 3 of 5
A 48-year-old woman with 2-year history of rheumatoid arthritis has not had sufficient relief with methotrexate alone. Her physician prescribes a biologic TNF-α inhibitor that consists of a recombinant human IgG fused to TNF-α receptor. Which of the following drugs is this?
Correct Answer: C
Rationale: Rheumatoid arthritis (RA) progression despite methotrexate warrants a TNF-α inhibitor. The description-recombinant human IgG fused to TNF-α receptor-points to Etanercept . Adalimumab and Golimumab are monoclonal antibodies against TNF-α, not receptor fusions. Certolizumab is a PEGylated Fab fragment, not IgG-based. Etanercept , a fusion protein, binds TNF-α, neutralizing it, and matches the question's structure. Infliximab (E) is a chimeric antibody. Etanercept's unique receptor-IgG design distinguishes it, effectively reducing RA inflammation by sequestering TNF-α, a key cytokine, making it the precise answer here.
Question 4 of 5
For which serious adverse effect should the nurse closely monitor a patient who is taking lincosamides?
Correct Answer: D
Rationale: Lincosamides, such as clindamycin, are associated with a high risk of Clostridium difficile-associated diarrhea (CDAD), a potentially life-threatening condition. CDAD occurs due to the disruption of normal gut flora, allowing C. difficile to overgrow and produce toxins. Symptoms include severe diarrhea, abdominal pain, and fever. While lincosamides can rarely cause hepatotoxicity or ototoxicity, CDAD is the most common and serious adverse effect. Seizures are not typically associated with lincosamides. Early identification and treatment of CDAD are crucial to prevent complications like toxic megacolon or sepsis.
Question 5 of 5
The physician ordered a brand name drug for the client, paroxetine (Paxil). After taking this medication for a year, the client tells the nurse that it is no longer working. What is the best assessment of the nurse at this time?
Correct Answer: B
Rationale: Paroxetine's effectiveness waning after a year suggests possible drug interactions reducing its levels or efficacy, a common issue needing assessment via medication review. Needing a change assumes a conclusion without evidence. Paxil and paroxetine are the same (brand vs. generic), making that question moot. Beck assessment evaluates depression, not drug failure. Interactions align with pharmacokinetic principles, offering a proactive step to identify culprits like enzyme inducers, critical for adjusting therapy.